The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults. The Food and Drug ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya, Janssen-Cilag Limited) for use in adults with Crohn’s disease and ulcerative colitis (UC). The drug is ...
Please provide your email address to receive an email when new articles are posted on . Patients treated with guselkumab vs. fumaric acid esters experienced greater improvement in PASI scores. When ...
SAN DIEGO, Calif.--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis ...
*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...
The decision is supported by the Phase 3 PROTOSTAR study, where guselkumab demonstrated higher levels of skin clearance vs. placebo at Week 16. 2 Almost one-third of Pso cases begin in childhood, and ...
Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Subcutaneous guselkumab induction and maintenance ...
Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 The decision is supported by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback